Nevro Announces Issuance of Additional Key U.S. Patents for Innovative Chronic Pain Treatment

Four Patents Offer Further Protection for Proprietary, High-Frequency Spinal Cord Stimulation (HF-SCS) Technology

January 24, 2013

Menlo Park, CA — Nevro Corp., a medical device company focused on improving the lives of patients suffering from debilitating chronic pain, announced today the issuance of four additional key patents related to the company’s Senza(R) system and HF10(TM) SCS therapy.

U.S. Patent No. 8,359,102 pertains to the basic methodology of treating a patient by delivering high-frequency spinal cord stimulation (HF-SCS) without generating paresthesia. The other three newly issued patents concern what appear to be distinct advantages of Nevro’s proprietary technology, including: (1) the ability to position leads along the spinal cord without the need for patient feedback or paresthesia mapping during the implantation process (U.S. 8,355,792); (2) the ability to deliver pain relief to both sides of the spinal cord through lateral placement of the stimulation lead (U.S. 8,359,103); and (3) the ability to automatically establish and generate stimulation parameters based on the patient’s status (U.S. 8,355,797). Further patent applications covering many other aspects of Nevro’s proprietary technology are pending in the U.S. and abroad.

Nevro’s Senza system is commercially available in Europe and Australia. In the U.S., the Senza system is presently under investigation as part of the U.S. SENZA-RCT clinical trial, a prospective, randomized, controlled pivotal clinical trial evaluating the system’s safety and effectiveness for the treatment of chronic pain.

About Nevro Corp.

Headquartered in Menlo Park, Calif., privately held Nevro Corp. is focused on the development and commercialization of high-frequency spinal cord stimulation for the effective treatment of challenging conditions such as chronic low back pain and other disorders while enhancing patient experience. The company has developed the only SCS system capable of delivering stimulation at a pulse frequency of up to 10 kHz and providing HF10(TM) SCS therapy. Nevro’s investors include Johnson & Johnson Development Corporation, Bay City Capital, Three Arch Partners, Aberdare Ventures, MPM Capital, and Accuitive Medical Ventures. For more information, please visit .
Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

Caution – Investigational device, limited by United States law to investigational use.

< Back to News & Events